drugset / Trial / NCT06298708

Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents

NCT06298708 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

Hepatitis A virus (HAV) vaccine is an effective strategy to prevent natural HAV infection. In Thailand, there are 2 types of HAV vaccine available, including inactivated HAV vaccine and live-attenuated HAV vaccine. This study aims to compare the immunogenicity and safety of inactivated and lived-attenuated HAV vaccine among Thai healthy children and adolescents age 18 months to 18 years.

Timeline

Start
2024-04-27
Primary completion
2024-12-09
Completion
2024-12-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator HAVRIX 720 Junior Vaccine 0.5 ml Intramuscular
Subject Mevac-A Vaccine 0.5 ml Subcutaneous